Jeffrey Kamlet, MD
Internal Medicine · Miami Beach, FLNPI 1124034673
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,288 of the $2,653 with a category attached, or 86.2%. It is spread thinly across 21 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $753 and has fallen 90.9% since, to $68 in 2024.
Across 122 payments — averaging $21.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$372
- C. R. Bard, Inc. & Subsidiaries$365
- Redhill Biopharma Inc.$365
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$335
- Alkermes, Inc.$257
- Scilex Pharmaceuticals Inc.$190
- plus $769 from 15 others
Across 1 payment — averaging $134.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$134
What the payments were for
- Consulting fees$36514%
- Food & beverage$2,28886%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 21 | $372 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $365 |
| Redhill Biopharma Inc. | 21 | $365 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $335 |
| Alkermes, Inc. | 13 | $257 |
| Scilex Pharmaceuticals Inc. | 10 | $190 |
| EMD Serono, Inc. | 6 | $164 |
| Idorsia Pharmaceuticals US Inc | 6 | $112 |
| Lilly USA, LLC | 6 | $90 |
| Forte Bio-pharma LLC | 3 | $77 |
| Orexo US, Inc. | 4 | $70 |
| Pfizer | 2 | $53 |
| GRT US Holding, Inc. | 2 | $38 |
| Amgen | 2 | $32 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $27 |
| Fidia Pharma USA Inc. | 1 | $24 |
| Novo Nordisk | 1 | $22 |
| IBSA Pharma Inc. | 1 | $18 |
| Gilead | 1 | $16 |
| Kaleo, Inc. | 1 | $13 |
| Radius Health, Inc. | 1 | $13 |
How this compares
$2,653 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ibuprofen | 14 | $143 |
| Gabapentin | 13 | $81 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Miami Beach
- Jason ShapiroMiami Beach$69K
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.